News
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Danish leader will face a challenging landscape among competitors ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk A/S (NYSE:NVO) is a prominent global healthcare company that focuses on treating rare diseases, diabetes, and ...
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...
Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback